Polymetastatic Recurrence-Free Survival in Patients with Repeat Oligometastases on the SABR-5 Trial
Wenxin Liu(Jiujiang University), Ming Liu, W. Jiang(Surrey Memorial Hospital), Benjamin Mou(University of British Columbia), Tanya Berrang, Salini Das(Chittaranjan National Cancer Institute), S. Tyldesley, E.M. Dunne, Jee Suk Chang(Yonsei University), Robert Olson(BC Cancer Agency), F. Hsu(Abbotsford Veterinary Clinic), Sarah Baker(Surrey Memorial Hospital), Devin Schellenberg(Surrey Place Centre), S. Lefresne
International Journal of Radiation Oncology*Biology*Physics
September 29, 2023
Cited by 1
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
|BMC Cancer|2012|308
Accuracy of genomic selection in European maize elite breeding populations
|Theoretical and Applied Genetics|2011|287
Mutation of ZmDMP enhances haploid induction in maize
|Nature Plants|2019|276